Pharmaceutical TechnologyPfizer starts $1.5bn cost-cutting initiative amidst declining Covid-19 revenuesMay 23Phalguni DeswalBy Phalguni Deswalmore_vert
Investing.com UKPfizer's Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions By BenzingaMay 23more_vert
QuartzOzempic knock offs; and Pfizer, AstraZenca's post-COVID erasMay 24Bruce GilBy Bruce Gilmore_vert
Regulatory FocusRecon: Pfizer looks to cut $1.5B in spending by 2027; Drugmakers prevail in first Zantac cancer trialMay 23more_vert
PharmaLivePfizer targets another $1.5B in cost cuts by end of 2027May 23Tristan ManalacBy Tristan Manalacmore_vert
CNBCPfizer aims to save $1.5 billion by 2027 in first wave of new cost cutsMay 22Annika Kim ConstantinoBy Annika Kim Constantinomore_vert
BenzingaPfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027 - Pfizer (NYSE:PFE)May 23more_vert
BioSpacePfizer Targets Another $1.5B in Cost Cuts By End of 2027May 23Tristan ManalacBy Tristan Manalacmore_vert
Yahoo FinancePfizer expands cost cuts with new $1.5B targetMay 22Ned PagliaruloBy Ned Pagliarulomore_vert
QuartzPfizer announces $1.5 billion cost-cutting program as vaccine sales fallMay 22Bruce GilBy Bruce Gilmore_vert
Yahoo! VoicesPfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027May 22more_vert